Preliminary analysis on the treatment of ventilator-associated pneumonia caused by pandrug-resistant Acinetobacter baumannii.
- Author:
Li-wan WANG
1
;
Lin ZOU
1
;
Hong-xia LI
1
;
Tian-zhi LI
1
Author Information
- Publication Type:Journal Article
- MeSH: Acinetobacter baumannii; Aged, 80 and over; Anti-Bacterial Agents; therapeutic use; Cefoperazone; therapeutic use; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Male; Minocycline; therapeutic use; Pneumonia, Ventilator-Associated; drug therapy; microbiology; Retrospective Studies; Sulbactam; therapeutic use; Treatment Outcome
- From: Acta Academiae Medicinae Sinicae 2014;36(2):185-188
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze the clinical features of pandrug-resistant Acinetobacter baumannii (PDR-Ab) in the Chinese PLA General Hospital and compare the efficacies of different antibiotic treatments in aged patients with ventilator-associative pneumonia (VAP) caused by PDR-Ab.
METHODSData were collected from all isolated PDR-Ab strains in our hospital from April 2009 to April 2010. The clinical features, treatment, and outcomes were retrospectively reviewed.
RESULTSPDR-Ab was found to be the dominant pathogen in 42 of 126 aged VAP patients. Cefoperazone/sulbactam plus minocycline showed good efficacy in 20 patients with PDR-Ab VAP, showing a clinical cure rate of 65% (13/20) and a bacterial eradication rate of 40% (8/20). Another 22 patients were treated with other antimicrobial drugs, achieving a clinical cure rate of 22.7% (5/22) and a bacterial eradication rate of 13.6% (3/22). The factors influencing bacterial clearance were prolonged length of hospital stay and mechanical ventilation prior to positive culture (all P<0.01).
CONCLUSIONCefoperazone/sulbactam plus minocycline can be an effective treatment for VAP caused by PDR-Ab.
